艾迪注射液联合XELOX方案对晚期结直肠癌患者肿瘤标志物、血管生成和外周血Th17/Treg平衡的影响

摘要 目的：观察艾迪注射液联合XELOX方案（卡培他滨+奥沙利铂）对晚期结直肠癌患者肿瘤标志物、血管生成和外周血辅助性T细胞17（Th17）/调节性T细胞（Treg）平衡的影响。方法：选择我院2018年2月~2019年8月期间收治的98例经内镜活检证实的晚期结直肠癌患者，根据随机数字表法分为对照组（XELOX方案化疗，49例）和研究组（艾迪注射液联合XELOX化疗方案治疗，49例）。观察两组患者近、远期疗效，对比两组治疗前后的肿瘤标志物、血管生成和Th17/Treg平衡相关指标水平，记录两组用药安全性。结果：与对照组相比，研究组的客观缓解率、疾病控制率明显更高（P<0.05）；研究组的总生存率、无进展生存率高于对照组，但两组间差异无统计学意义（P>0.05）。治疗后，两组癌胚抗原（CEA）、糖链抗原125（CA125）、糖链抗原242（CA242）水平均下降，且研究组低于对照组同期（P<0.05）。治疗后，两组血管内皮生长因子（VEGF）、肿瘤微血管密度（MVD）水平均下降，且研究组低于对照组同期（P<0.05）。治疗后，两组Th17比例、Th17/Treg比值均升高，Treg比例均下降（P<0.05）；研究组治疗后Th17比例、Th17/Treg比值高于对照组同期，Treg比例低于对照组同期（P<0.05）。两组不良反应总发生率对比未见明显差异（P>0.05）。结论：艾迪注射液联合XELOX方案治疗晚期结直肠癌的疗效确切，可能与改善Th17/Treg平衡、抑制血管生成有关。

Effects of Aidi Injection Combined with XELOX Regimen on Tumor Markers, Angiogenesis and Peripheral Blood Th17/Tregg Balance in Patients with Advanced Colorectal Cancer

ABSTRACT Objective: To observe the effects of Aidi injection combined with XELOX regimen (capecitabine combined with oxaliplatin) on tumor markers, angiogenesis and peripheral blood helper T cell 17 (Th17) / regulatory T cell (Treg) balance in patients with advanced colorectal cancer. Methods: 98 patients with advanced colorectal cancer confirmed by endoscopic biopsy in our hospital from February 2018 to August 2019 were selected as the research objects. According to the random number table method, they were divided into control group ( XELOX regimen chemotherapy, 49 cases) and study group (Aidi injection combined with XELOX chemotherapy regimen, 49 cases). The short-term and long-term efficacy of the two groups were observed, the levels of tumor markers, angiogenesis and Th17 / Treg balance of the two groups were compared before and after treatment, and the drug safety of the two groups was recorded. Results: Compared with the control group, the objective remission rate and disease control rate of the study group were significantly higher (P<0.05). The overall survival rate and progression free survival rate of the study group were higher than those of the control group, but there was no significant difference between the two groups (P>0.05). After treatment, the levels of carcinoembryonic antigen (CEA), sugar chain antigen 125 (CA125) and sugar chain antigen 242 (CA242) of the two groups decreased, and the study group was lower than the control group in the same period (P<0.05). After treatment, the levels of vascular endothelial growth factor (VEGF) and tumor microvessel density (MVD) decreased in the two groups, and the study group was lower than the control group in the same period (P<0.05). After treatment, Th17 ratio and Th17/Treg ratio increased, and Treg ratio decreased in the two groups (P<0.05). After treatment, the Th17 ratio and Th17/Treg ratio of the study group were higher than those of the control group in the same period, and the Treg ratio was lower than that of the control group in the same period (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Aidi injection combined with XELOX regimen is effective in the treatment of advanced colorectal cancer, which may be related to improving Th17/Treg balance and inhibiting angiogenesis.